About Trestle Biotherapeutics
Trestle Biotherapeutics develops an implantable therapeutic tissue that can be surgically delivered to patients suffering from end-stage renal disease. Its services offer the development of functional therapeutic tissue for patients suffering from chronic kidney disease through the integration of stem cell biology and bio-fabrication. The company was founded in 2023 and is based in San Diego, California.
Expert Collections containing Trestle Biotherapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Trestle Biotherapeutics is included in 1 Expert Collection, including Y Combinator W21 Demo Day.
Y Combinator W21 Demo Day
Latest Trestle Biotherapeutics News
Jun 12, 2023
SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics today received a $1 million prize from the KidneyX Innovation Accelerator through the organization’s Artificial Kidney Prize program. Trestle is one of eight Artificial Kidney Prize Phase 2 winners announced today. Trestle was recognized for their innovative approach in developing bioengineered kidney tissues for patients living with kidney failure through the integration of cutting-edge techniques in stem cell biology and 3D biofabrication. T
Trestle Biotherapeutics Frequently Asked Questions (FAQ)
When was Trestle Biotherapeutics founded?
Trestle Biotherapeutics was founded in 2020.
Where is Trestle Biotherapeutics's headquarters?
Trestle Biotherapeutics's headquarters is located at 9276 Scranton Road, San Diego.
What is Trestle Biotherapeutics's latest funding round?
Trestle Biotherapeutics's latest funding round is Biz Plan Competition.
How much did Trestle Biotherapeutics raise?
Trestle Biotherapeutics raised a total of $1.13M.
Who are the investors of Trestle Biotherapeutics?
Investors of Trestle Biotherapeutics include KidneyX Artificial Kidney Prize, Wellcome Leap HOPE Program, Y Combinator, Black Mountain Ventures, Formic Ventures and 5 more.